Geode Capital Management LLC Lowers Position in Altimmune, Inc. (NASDAQ:ALT)

Geode Capital Management LLC trimmed its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 0.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,658,506 shares of the company’s stock after selling 9,498 shares during the quarter. Geode Capital Management LLC owned approximately 2.33% of Altimmune worth $11,961,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune in the fourth quarter worth about $45,000. Cullen Frost Bankers Inc. acquired a new position in Altimmune in the 4th quarter worth about $72,000. 180 Wealth Advisors LLC acquired a new position in Altimmune in the 4th quarter worth about $78,000. KLP Kapitalforvaltning AS purchased a new position in Altimmune during the fourth quarter worth approximately $81,000. Finally, Raymond James Financial Inc. acquired a new stake in Altimmune in the fourth quarter valued at approximately $88,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ALT shares. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Finally, Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.83.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was bought at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is owned by insiders.

Altimmune Price Performance

Shares of Altimmune stock opened at $4.79 on Tuesday. The stock’s 50 day simple moving average is $5.38 and its 200-day simple moving average is $6.73. The stock has a market cap of $368.90 million, a P/E ratio of -3.09 and a beta of 0.91. Altimmune, Inc. has a 1-year low of $3.55 and a 1-year high of $11.16.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.